EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC-ND 4.0

Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect

Lin Zhu, Kaiqing Yang, Zhe Ren, Detao Yin, Yubing Zhou

Translational Oncology · 2024-06 · 44 · 101945

DOI: 10.1016/j.tranon.2024.101945 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Translational Oncology, 2024-06. Verfasst von Lin Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, PR China. Die Arbeit wurde bisher 82-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metformin, as the preferred antihyperglycemic drug for type 2 diabetes, has been found to have a significant effect in inhibiting tumor growth in recent years. However, metformin alone in cancer treatment has the disadvantages of high dose concentrations and few targeted cancer types. Increasing studies have confirmed that metformin can be used in combination with conventional anticancer therapy to obtain more promising clinical benefits, which is expected to be rapidly transformed and applied in clinic. Some combination therapy strategies including metformin combined with chemotherapy, radiotherapy, targeted therapy and immunotherapy have been proven to have more significant antitumor effects and longer survival time than monotherapy. In this review, we summarize the synergistic antitumor effects and mechanisms of metformin in combination with other current conventional anticancer therapies. In addition, we update the research progress and the latest prospect of the metformin-combined application in the cancer treatment. This work could provide more evidence and future direction for the clinical application of metformin in antitumor.

Schlagwörter

Stichwörter der Autor:innen

CancerChemotherapyCombination therapyImmunotherapyMetforminRadiotherapyTargeted therapy

Autor:innen und Institutionen

  • Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, PR China.
  • Department of Thyroid Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, PR China. Electronic address: detaoyin@zzu.edu.cn.
  • Department of Pharmacy, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, Henan, PR China. Electronic address: fcczhouyb@zzu.edu.cn.

Förderung

  • National Natural Science Foundation of China

Zitieren

APA

Zhu, L., Yang, K., Ren, Z., Yin, D., & Zhou, Y. (2024). Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect. Translational Oncology, 44, 101945. https://doi.org/10.1016/j.tranon.2024.101945

Vancouver

Zhu L, Yang K, Ren Z, Yin D, Zhou Y. Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect. Translational Oncology. 2024;44:101945. doi:10.1016/j.tranon.2024.101945

BibTeX
@article{Zhu2024,
  author = {Zhu, Lin and Yang, Kaiqing and Ren, Zhe and Yin, Detao and Zhou, Yubing},
  title = {Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect},
  journal = {Translational Oncology},
  year = {2024},
  volume = {44},
  pages = {101945},
  doi = {10.1016/j.tranon.2024.101945}
}
Kostenlos starten →